Although the rates of progression to stage 3 T1D were similar in both groups, inthose with insulin autoantibody (IAA) levels ≥ 80 nU/mL (n =263), there was a trend suggesting benefit in the annual risk of progression to clinicaldisease (71). The gene discussed is INS; the disease is type 1 diabetes mellitus.